AMARIN CORP PLC\UK — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Amarin reported Q2 2026 revenue of $42.2M (down 42% YoY from $72.7M), with the decline driven by absence of a $25M upfront Recordati payment received in Q2 2025 and $22.3M licensing revenue drop. Operating expenses fell 59% to $27.0M (excluding restructuring, 38% decline aligned with completed $70M cost-reduction plan). Cash grew 5% to $314.6M from $298.7M; the company remained debt-free and generated positive cash flow for the third consecutive quarter. Key operational wins: global partner in-market demand rose 59% YoY, U.S. market share increased to 48%, Europe demand up 69%, and 22 countries now commercialize VASCEPA/VAZKEPA (11 in Europe via Recordati partnership initiated June 2025).
Why this rating
Significant cost restructuring (now complete) and positive cash generation are favorable structural improvements. However, 42% revenue decline and continued operating losses ($12M Q2) offset gains. One-time Recordati upfront payment masks underlying weakness; product revenue down 16%. European partnership is early-stage and unproven. Modest cash position ($314.6M, ~94% of market cap) limits duration of losses. Results show stabilization but no clear path to profitability yet.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.